Testing one extra small dose of radiation for adults with newly diagnosed glioblastoma
Official title: REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing whether one extra radiation treatment after standard care is safe and practical.
Read our full plain-language summary
What the trial team says
REMIND is a single-center feasibility study testing maintenance radiotherapy in adult patients with newly diagnosed glioblastoma. Participants will be consented before starting standard-of-care concurrent temozolomide and radiotherapy. After enrollment, participants will enter an observational lead-in phase while receiving standard-of-care therapy off study. Approximately 4 weeks after temozolomide, participants will receive one study-specific 2 Gy fraction of maintenance radiotherapy directed at the post-operative cavity and areas of prior enhancing disease. The study will evaluate the safety and feasibility of delivering maintenance radiotherapy. Blood samples will also be collected before and after maintenance radiotherapy to descriptively compare myeloid-derived suppressor cell frequency.
Key facts
- Registry number
- NCT07831772
- Stage of testing
- Not applicable
- Conditions studied
- Glioblastoma, Newly Diagnosed Glioblastoma, Brain Tumor
Where it is running
This trial lists 1 site.
-
Minnesota
- University of Minnesota Radiation Oncology (Minneapolis)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.